A detailed history of Principal Securities, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 594 shares of EXEL stock, worth $21,342. This represents 0.0% of its overall portfolio holdings.

Number of Shares
594
Previous 472 25.85%
Holding current value
$21,342
Previous $10.6 Million 45.33%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$21.96 - $27.6 $2,679 - $3,367
122 Added 25.85%
594 $15.4 Million
Q2 2024

Jul 31, 2024

SELL
$20.34 - $23.73 $8,949 - $10,441
-440 Reduced 48.25%
472 $10.6 Million
Q1 2024

May 10, 2024

BUY
$20.17 - $23.93 $13,695 - $16,248
679 Added 291.42%
912 $21.6 Million
Q4 2023

Feb 07, 2024

BUY
$19.25 - $24.13 $4,485 - $5,622
233 New
233 $5.59 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Principal Securities, Inc. Portfolio

Follow Principal Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.